Endo completed the acquisition of the six development-stage, ready-to-use injectable product candidates of Nevakar Injectables for $35m.

Endo, a specialty pharmaceutical company, completed the acquisition of the six development-stage, ready-to-use injectable product candidates of Nevakar Injectables, a biopharmaceutical company, for $35m. "These six product candidates that would be used in critical care settings meaningfully expand Endo's ready-to-use injectable product pipeline. We look forward to further developing and bringing these durable and differentiated products to market—and to the healthcare providers and patients who need them," Scott Sims, Endo Senior Vice President and General Manager in Injectable Solutions & Generics.